University of Patras
Φαρμακογονιδιωματική ανάλυση με αλληλούχιση νέας γενιάς: κλινικές εφαρμογές και ρυθμιστικές προεκτάσεις
Abstract
dc:descriptionThe utilization of genotype-guided psychiatric medication therapy remains limited within the field of psychiatry. However, a number of newly published randomized controlled trials (RCTs) indicate that the use of genotype-guided decision- making in prescription psychiatric medications may lead to improved treatment outcomes compared to the traditional treatment-as-usual method. Additionally, these studies imply that such an approach might be cost-effective. A more comprehensive comprehension of the etiology underlying the hereditary pharmacokinetic variability of psychiatric medications is imperative in order to develop more refined decision support tools and dosage recommendations. Presently, our ability to elucidate genetic factors responsible for interindividual variations in pharmacokinetic parameters is limited to less than 50%. In addition, the successful integration of pharmacogenomics into the field of psychiatry necessitates the involvement of highly knowledgeable and driven physicians, with the endorsement and assistance of patient advocacy groups. Undoubtedly, pharmacogenomics (PGx) aims in optimizing drug treatment responses whilst also improving the patients’ quality of life, either via a reduction of adverse drug reactions and/or an enhancement of drug treatment efficacy. To achieve this, PGx guidance is provided by the two major regulatory bodies in a worldwide level, specifically the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA), and occasionally some research consortia, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) or the Dutch Pharmacogenomics Working Group (DPWG). However, so far, there is a limited number of studies focusing on the delineation of the similarities and more importantly, the discrepancies in the PGx guidance by the different regulatory bodies and consortia. Herein, we use real-life clinical PGx data to highlight such discrepancies and similarities for genome-guided interventions in psychiatric disorders, thus demonstrating the need for harmonization of the guidelines and recommendations. More precisely, we used the Pharm CAT genome- informed drug treatment reports from 304 Greek individuals with bipolar disorder, schizophrenia and major depressive disorder, in order to emphasize on the discrepancies in the PGx guidance/guidelines between FDA vs EMA and CPIC vs DPWG, respectively. For example, CYP2D6-pimozide pair is characterized as ‘Testing Required’ according to FDA and is accompanied by a DPWG PGx guideline, whilst no EMA or CPIC PGx guidance is found for this drug-gene pair. Moreover, discrepancies are observed regarding the type of PGx guidance for CYP2C19-doxepin pair, with 89 individuals from our study cohort requiring a dose prescribing change based on FDA, whilst only 5 individuals have to receive genome-guided treatment adjustment according to CPIC. To our knowledge, this is the first study, in which discrepancies regarding the type of PGx guidance and the number of actionable drug-gene pairs amongst FDA and EMA, as well as CPIC and DPWG, are brought to light with an emphasis on psychiatric disorders. It is posited that the foreseeable future holds promise for the expanded implementation of genetically based psychiatric medication therapy, hence enhancing the efficacy of psychiatric treatment and yielding favorable outcomes. This advancement is anticipated to result in diminished expenses associated with psychiatric drug treatment and an overall enhancement of mental well-being within the population.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kordou, Zoi
- Κορδού, Ζωή
Subjects
dc:subject × 16- Φαρμακογονιωματική
- Αλληλούχιση νέας γενιάς
- Ψυχιατρικές διαταραχές
- Φαρμακογονίδια
- Ρυθμιστικές αρχές
- Pharmacogenomics
- Next generation sequencing
- Pharmacogenes
- Psychiatric disorders
- Regulatory authorities
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φαρμακολογία και Φαρμακευτική
- Basic Medicine
- Medical and Health Sciences
- Pharmacology and Pharmacy
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58615